SAN FRANCISCO, Jan 13 (Reuters) - AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as the drug industry increases its use of artificial intelligence to accelerate the discovery of new drugs.
The companies did not disclose financial terms. In a press release, Modella AI said its "foundation models" and AI agents would be integrated into oncology research and development to support clinical development and biomarker discovery.
"Oncology drug development is becoming more complex, more data-rich and more time-sensitive," said Gabi Raia, Modella AI's chief commercial officer, adding that joining AstraZeneca would allow it to deploy its tools in global trials and clinical settings.
AstraZeneca said that this was the first acquisition of an AI firm by a big pharmaceutical company.
In an interview at the JP Morgan Healthcare Conference, AstraZeneca Chief Financial Officer Aradhana Sarin said the acquisition would "supercharge" the company's quantitative pathology and biomarker discovery efforts by bringing more data and AI capabilities in-house.
The deal was one of a number of pacts between major drug firms and AI companies that were unveiled at the healthcare conference, including a $1 billion collaboration between Nvidia and Eli Lilly. They plan to build a new research lab using Nvidia's latest-generation AI chips.
Modella will accelerate AstraZeneca’s efforts to make pathology more quantitative - using computers to analyze biopsies for relevant proteins and correlate them with clinical data - so AstraZeneca can develop “highly targeted biomarkers and then highly targeted therapeutics,” Sarin said.
The deal is an expansion of a multi-year collaboration that the companies unveiled in July.
Sarin said that partnership served as a "test drive," adding that AstraZeneca ultimately wanted Modella's data, foundation models and AI talent in-house.
She said AI tools could be used to more rapidly select patients for drug trials, which could increase the odds of clinical success and cut related costs.
(Reporting by Maggie Fick; Editing by Thomas Derpinghaus)
LATEST POSTS
- 1
The Most Well known Online Entertainment Forces to be reckoned with of 2023 - 2‘We are the alternative’: Anti-Hamas Gaza militia tells BBC group is receiving international support
- 3Instructions to Utilize Your Brain science Certification to Work on Corporate Culture
- 4Material of Innovativeness: A Survey of \Releasing Your Imaginative Potential\ Online Workmanship Course
- 510 Famous Frozen yogurt Flavors All over The Planet
- The Best Computer games Ever
- This Miraculous, Cliff-Perched Town In The South Of France Is A Sacred European Gem
- 2 of Earth's rarest lightning phenomena captured simultaneously in once-in-a-lifetime photo
- Virtual reality opens doors for older people to build closer connections in real life
- German Cabinet advances bill to cut greenhouse emissions from fuels
- What's Your Number one Superhuman Film Made?
- Satellite constellations could obscure most space telescope observations by late 2030s: 'That part of the image will be forever lost'
- Quantum Computing’s Next Major Breakthroughs Could Come From Australia
- French lawmakers narrowly approve health care budget, suspending Macron's flagship pension reform
